Roche, Blueprint raise pressure on Lilly with new Gavreto ap...

The FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting it on a level playing field with Eli Lilly’s rival therapy Retevmo.<

AZ firms up immuno-oncology imaging deal with ImaginAb

PREDiCT: Imaging Modalities for Oncology Drug Development

Guiding Your Strategic Approach of Multimodal Imaging

FDA approves Caption Health's AI-driven cardiac ultrasound s...

The FDA has approved software from medical artificial intelligence (AI) firm Caption Health, that allows medical professionals without specialised training to perform cardiac ultrasound.

Harnessing the digital transformation of the drug developmen...

We have the evidence base to support the digital transformation of clinical trials – what we need now is the courage and the regulatory framework.

Can in vivo imaging deliver the full potential of immunother...

In the quest to control cancer we now face the challenge of translating our increasing insights into the cancer-immunity cycle into more effective immune therapies.